Table 5 Management of Pain: percentage of participants in panel 1 and 2 in favor of including the item, and median Dublin Descriptor
% in favor for inclusion | Dublin Descriptors | |||||
|---|---|---|---|---|---|---|
Panel 1 | Panel 2 | Total | Panel 1 | Panel 2 | Comment | |
A.Goals of Pain Management. | ||||||
1. Prevention and/or reduction of pain intensity. | 86 | 93 | 90 | 3 | 3 | |
2. Enhancement of physical functioning. | 100 | 93 | 95 | 3 | 3 | |
3. Improvement of psychological functioning. | 100 | 93 | 95 | 2 | 2 | |
4. Promotion of return to work/school and/or role within the family/society. | 100 | 93 | 95 | 3 | 3 | |
5. Improvement of health-related quality of life. | 100 | 93 | 95 | 3 | 3 | |
B. Pain Management Planning Decision. | ||||||
1. Develop, monitor and modify the management plan as an interprofessional and/or multiprofessional team. | 100 | 79 | 86 | 2 | 2 | |
2. Involve patient and family caregivers in establishing clear, realistic goals. | 100 | 93 | 95 | 3 | 3 | |
3. Use combinations of methods where appropriate including physical, psychological, pharmacological and interventional. | 100 | 86 | 90 | 2 | 2 | |
4. Provide patient information/education including: communication methods, management options, management of potential adverse effects. | 100 | 100 | 100 | 3 | 3 | |
5. Develop transparent treatment plan with realistic goals. | 100 | 79 | 80 | 3 | 3 | |
C. Treatment Considerations. | ||||||
1. Type(s) of pain. | 100 | 86 | 90 | 2 | 2 | |
2. Multidimensional nature of pain (e.g. Biological, psychological, social) Use of combinations of pharmacological and non-pharmacological methods. | 100 | 100 | 100 | 3 | 3 | |
D. Patient issues. | 86 | 86 | 86 | 2 | 2 | |
E. Caregiver issues. | 86 | 86 | 86 | 2 | 2 | |
F. Health professional issues. | 86 | 93 | 90 | 2 | 2 | |
G. Political issues. | 71 | 79 | 76 | 1 | 1 | |
H. Substance use disorders / abuse issues. | 57 | 64 | 60 | excluded | ||
I. Consider Non and use non-pharmalocial /interventional stategies (not in old version). | ||||||
J. Pharmacological Methods. | 57 | 43 | 48 | excluded | ||
K. Clarify tolerance, physical dependence and psychological dependence. | 29 | 79 | 62 | excluded | ||
L. Utilize combinations of analgesics and adjuvants where appropriate. | 29 | 43 | 38 | excluded | ||
M. Knowledge of legislative requirements and current guidelines regarding controlled drugs. | 29 | 21 | 24 | – | excluded | |
N. Non-pharmacological and intervention methods. | ||||||
1. a. Clinician therapeutic use of self . | 100 | 93 | 95 | 3 | 3 | |
1. b. Physical strategies to support home and occupational function and activity. | 100 | 86 | 90 | 3 | 3 | |
1.c.Psychological and behavioral strategies | 100 | 100 | 100 | 3 | 3 | |
1.d.I.Neuromodulation | 71 | 79 | 76 | 2 | 2 | |
1.d.II.Neuroablative strategies | 71 | 50 | 57 | excluded | ||
1.d.III.Procedural/Interventional | 71 | 57 | 62 | excluded | ||
1.d.IV.Surgery | 86 | 50 | 62 | excluded | ||
1.d.v. Palliative Radiotherapy | 71 | 50 | 57 | excluded | ||
2.Complementary alternative medicine (CAM) | 57 | 46 | 57 | excluded | ||
3. Information and communication technologies | 100 | 57 | 71 | 3 | 3 | |
O. Evaluation of outcome | ||||||
1. Monitor management outcomes . | 86 | 79 | 81 | 3 | 3 | |
2.Utilize an interprofessional and multiprofessional team approach | 71 | 93 | 86 | 2 | 2 | |
3.Consider barriers related to treatment availability and costs at the patient-family, institution, society and government levels | 57 | 57 | 57 | excluded | ||